Talaris Therapeutics (Talaris Therapeutics) EBIT : $-69.36 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Talaris Therapeutics EBIT?

Talaris Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2023 was $-10.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-69.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Talaris Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 was -545.27%. Talaris Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1,725.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Talaris Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 225.38%.

Talaris Therapeutics EBIT Historical Data

The historical data trend for Talaris Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talaris Therapeutics EBIT Chart

Talaris Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EBIT

-18.38

-22.68

-47.51

-76.48

Talaris Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBIT	Get a 7-Day Free Trial										-18.42	-19.82	-19.83	-19.60	-10.11

Competitive Comparison of Talaris Therapeutics's EBIT

For the Biotechnology subindustry, Talaris Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talaris Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Talaris Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Talaris Therapeutics's EV-to-EBIT falls into.

Talaris Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.36 Mil.

Talaris Therapeutics (NAS:TALS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Talaris Therapeutics's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-40.456 * ( 1 - 0% )	/	( (7.698	+	7.141)	/ 2 )
=	-40.456	/	7.4195
=	-545.27 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	172.607	-	6.228	-	( 165.813	-	max(0, 10.179	-	168.86	+	165.813	))
=	7.698

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	159.121	-	5.907	-	( 152.252	-	max(0, 10.134	-	156.207	+	152.252	))
=	7.141

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Talaris Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-40.456	/	( ( (3.636 + max(-6.381, 0))	+	(1.053 + max(-5.578, 0)) )	/	2 )
=	-40.456	/	( ( 3.636	+	1.053 )	/	2 )
=	-40.456	/	2.3445
=	-1,725.57 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.047)	-	(6.228	+	0	+	3.2)
=	-6.381

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	3.955)	-	(5.907	+	0	+	3.626)
=	-5.578

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Talaris Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2023 )
	=	-69.359	/	-30.774
	=	225.38 %

Talaris Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Talaris Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Talaris Therapeutics (Talaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Talaris Therapeutics Inc (NAS:TALS) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

93 Worcester Street, Wellesley, MA, USA, 02481

Website

https://www.talaristx.com

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Executives

Cariad Chester	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Yung H. Chyung	officer: Chief Medical Officer	C/O SCHOLAR ROCK, 620 MEMORIAL DR., 2ND FLOOR, CAMBRIDGE MA 02139
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
W Bradford Middlekauff	officer: CBO, GC and Secretary	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Sandeep Chidambar Kulkarni	director, officer: CEO	92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kevin Bruce Johnson	officer: Chief Regulatory Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Ryan F. Robinson	officer: Interim CFO	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Parvinder Thiara	director	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Susan Dana Jones	officer: Chief Technology Officer	C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Suzanne Ildstad	director, 10 percent owner, officer: Chief Scientific Officer	C/O TALARIS THERAPEUTICS, INC., 93 WORCESTER STREET, SUITE 120, WELLESLEY MA 02481
Scott Requadt	director, officer: See Remarks	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025